Vetoquinol has announced the launch of Chrysanphyton, the latest addition to its range of Equistro feeding stuffs for horses.
Vetoquinol says Chrysanphyton is recommended for horses where support of a normal blood flow to the hoof is important. It contains Chrysantellum americanum, blackcurrant and hazelnut extracts which, according to the company, provide a rich source of nutrient bioflavanoids and vitamins.
The recommended administration of Chrysanphyton is 10ml twice a day in horses (500kg) and 5ml twice a day in ponies with the 1000ml pack lasting 50 or 100 days respectively.
A product information sheet is available on the Equistro website www.equistro.co.uk
For further information contact your local Vétoquinol Territory Manager.
The Animal Health Trust is appealing to veterinary surgeons and nurses to encourage clients who keep their horses on premises that have been affected by Equine Grass Sickness to sign up to the second year of its nationwide EGS vaccine trial.
Equine Grass Sickness (EGS) occurs predominantly in Europe, with Britain experiencing the highest incidence worldwide. In 2014, 59 cases of EGS were reported through the EGS Surveillance Scheme, but it is likely that this represents only a fraction of cases occurring annually throughout Britain.
Almost all cases of EGS occur in horses with access to grazing. The AHT says there is growing scientific evidence to suggest that the disease may be caused by the bacterium Clostridium botulinum type C, commonly found within soil and capable of producing neurotoxins to which horses are particularly sensitive. EGS occurs when a combination of risk factors trigger the production of these toxins within the horse's intestinal tract, causing damage to the nervous system and paralysis of the gut.
As similar equine diseases such as tetanus and botulism can be prevented by vaccination, it is theoretically possible that a vaccine could prevent EGS. To this end the AHT, in collaboration with the Universities of Edinburgh, Liverpool and Surrey launched the EGS field vaccine trial in 2014 in order to establish whether a vaccine could indeed be effective in reducing the risk of the disease. The trial is funded by a number of sources including Neogen Corporation; Animal Welfare Foundation; Horserace Betting Levy Board; Racing Foundation; Moredun Foundation Equine Grass Sickness Fund; Hong Kong Jockey Club; The British Horse Society and the EB Moller Charitable Trust.
Now entering its second year, the EGS vaccine trial involves enrolled horses and ponies receiving either a course of the C. botulinum type C toxoid vaccine or an inactive placebo, as well as an annual booster. The incidence of EGS is monitored throughout the trial to determine the efficacy of the vaccine, and enrolled horses and ponies are closely monitored through regular follow-ups for the duration of the trial.
With 60% of EGS cases occurring during April - June, the highest risk season for EGS is fast approaching. The AHT is appealing to owners who keep their horses on premises that have had at least one case of EGS in the past three years to enrol their horse in the vaccine trial and provide an invaluable contribution to this pioneering research prior to these high risk months. Veterinary practices with clients who fit this description are asked to help the recruitment process by encouraging suitable cases to sign up to the trial.
Dr Jo Ireland, the AHT's Equine Grass Sickness Research Co-ordinator, said: "We have been delighted with the overwhelmingly positive response to the EGS vaccine trial and many owners have welcomed the chance to be a part of such important research. We don't want any eligible horse owners to miss out on the opportunity to contribute towards a potential breakthrough in the prevention of EGS, so we are encouraging more owners to enrol their horses on the trial this year."
To find out more about the vaccine trial or how clients can enrol horses and ponies, visit the AHT's dedicated EGS website www.equinegrasssickness.co.uk or email equinegrasssickness@aht.org.uk.
Rabbit Viral Haemorrhagic Disease variant (RVHD2) is a variation of the already recognised Rabbit Viral Haemorrhagic Disease (RVHD1). Vaccines for the original strain of RVHD do not appear to offer long term protection against RVHD2, however vaccines for this new strain are now available in the UK and can be purchased through three UK wholesalers (NVS, Centaur and Henry Schein Animal Health) or direct from the suppliers in Europe. There have been supply issues with this vaccination, however these are hoping to be remedied soon.
RVHD2 is more variable in its rate of disease progression than RVHD1, with presentation ranging from sudden death (with or without bleeding from the orifices), to a longer disease course of three to nine days, increasing the risk of unwell rabbits being brought into practices and in turn increasing the risk of transmission to other pet rabbits. Until vaccination becomes more routine, biosecurity in practices is key to prevent the disease from spreading.
Sean Wensley, BVA President, said: "Although the risk of a rabbit contracting RVHD2 appears highest in situations where rabbits are kept in large groups with regular new additions, such as at breeders or rescue centres, we encourage all owners to speak to their vet about vaccinating their rabbits against RVHD2.
"Veterinary advice from The Rabbit Welfare Association and Fund (RWAF) has stated that the spread of RVHD2 may be facilitated by its apparent slower disease progression compared to RVHD1, and research suggests that we can expect to see RVHD2 starting to predominate in the UK’s wild rabbits over RVHD1 in the next five years or so."
John Chitty, BSAVA Vice President, said: "BSAVA would encourage practices to talk to rabbit owning clients about RVHD2 vaccines, and where there is deemed sufficient risk recommend the vaccine along with the essential vaccination against Myxomatosis – and it should be noted that this must not be done within two weeks of vaccination against RVHD2."
BVZS President and veterinary pathologist Mark Stidworthy said: "It is clear from post mortem examinations and PCR testing over the last 18 months that RVHD2 is now geographically widespread in the UK and all rabbits should be considered at risk from this potentially devastating disease."
Due to recent media coverage of RVHD2, vets may be contacted by concerned owners seeking advice on how to prevent their rabbits contracting this disease - further to vaccinating, vets should recommend rabbits are kept separate from any other rabbits they do not usually interact with; are prevented from having contact with wild rabbits and do not attend any rabbit shows unless already vaccinated.
For a detailed Q&A on RVHD2 from Richard Saunders MRCVS, veterinary advisor to the RWAF, including information on sourcing effective vaccines, visit www.rabbitwelfare.co.uk and click RVHD2 - Filavac Vaccine – FAQs on the home page.
Photo: Larry D. Moore CC BY-SA 3.0.
The range comprises of a detangling pre-wash, a cleansing shampoo and a fragrant conditioner, all of which are pH balanced and formulated using natural ingredients and a blend of essential oils designed to make bathtime a calmer experience.
The products all come in 300ml bottles with a list price of £6; RRP £12.
The Pet Remedy range can be ordered direct from Animalcare on 01904 487687 (orders@animalcare.co.uk) or from your veterinary wholesaler.
8,834 of the 33,857 eligible voters cast their votes, a turnout rate of 26.2%. This compares to a 25.5% turnout in the 2019 election and 22.7% in 2018.
The results of the election were as follows:
Dr Kate Richards (pictured right) – 4,399 votes (elected)Dr Richard Stephenson – 3,943 votes (elected)Dr Melissa Donald – 3,807 votes (elected)Professor Stephen May – 3,121 votesDr Kit Sturgess – 2,816 votesPeter Robinson – 2,642 votesJohn Davies – 808 votesDr Tom Lonsdale – 535 votes
Eleanor Ferguson, RCVS Registrar and Returning Officer for both elections, said: “Many congratulations to all those who were elected this year and we look forward to welcoming them to their places on Council at our Annual General Meeting later this year.
“I would like to thank both Professor Stephen May and Dr Kit Sturgess for their many years of combined service, both as members of RCVS Council and for serving on numerous committees, subcommittees and working groups. In Stephen’s case this includes his service as President of the RCVS in 2017-18 and for Kit as Treasurer of the RCVS from 2017 until the present.
As Dr Sturgess had been elected to the position of Junior Vice-President of the RCVS for 2020-21 earlier this year, a new election for the position will need to take place amongst RCVS Council members during their June meeting. An election for a new Chair and Vice-Chair of VN Council will take place take place amongst VN Council members at a meeting in June.
The information has been made available amid concerns from behaviourists and animal welfare organisations that there may be a rise in behavioural issues as lifestyle restrictions are lifted.
The Q&A explains what some of the behavioural concerns are and how they can be prevented and managed. Topics include separation-related issues, animals becoming anxious as the world around them becomes busier and noisier, and puppies lacking appropriate skills when greeting animals (including dogs and people) from other households.
The Q&A can be downloaded here.
Dr Hannah Donovan, vet, clinical animal behaviourist and Social Media Officer at the BVBA said: “We hope that this information will help vets to support their clients and their pets when faced with potential challenges as we transition out of lockdown.”
Professor Ian Ramsey, President of the BSAVA added: “This guidance has been developed in collaboration with the BVBA with the intention of supporting vets in practice in an ever-changing environment. It sits alongside other practical BSAVA resources vets can share with pet owners, such as Vaccination Guidance and Neutering Guidance, and follows the BSAVA’s core ethos – ‘By the profession for the profession.”
The BSAVA has also created a collection of resources for veterinary professionals relating to the prevention, management and treatment of behavioural issues in cats of dogs, which is freely available in the BSAVA Library until the end of July.
The collection includes chapters from the BSAVA Manual of Canine and Feline Behavioural Medicine; for those wishing to buy the full manual, there is a £10 discount on both the print and online editions throughout July (using code BEHAV10 on checkout).
Further information for vets can be found in the BSAVA’s COVID-19 resources here.
The GDP offers one-to-one mentoring, alongside professional and clinical skills development in primary care practices across the UK.
Chloe Roberts, clinical and educational development manager at Linnaeus, said: “This fourth cohort of graduates is looking likely to be the biggest yet, which is testament to how successful the programme has become over recent years.
“We’ve received so many high-quality applications and look forward to welcoming many of them into our practices.
“There’s still time left for people to apply via our online portal, so we’d love to hear from any prospective candidates interested in roles in the Midlands and Yorkshire.”
Linnaeus delivers all clinical training in-house through its extensive network of specialists, referral clinicians, certificate holders and experienced primary care clinicians.
Graduates take part in 20 core educational days as part of their clinical and professional skills training, with access to an additional 10 CPD days to undertake training of their own choice over the course of the programme.
For more information about the Graduate Development Programme, visit https://graduates.linnaeusgroup.co.uk.
Photo: Bristol University graduate Abigail McCarthy, a vet at Blacks Vets in Dudley
According to MORE TH>N pet insurance, men aren't just upset by the loss of a pet, 13% of them take a week or more off work if their pet is lost or stolen.
Notably, that compares to just 5% of women who have taken that much time off work to get over the upset caused by a pet going missing or being stolen.
According to the company, men are also more likely to cancel social engagements if a pet goes missing (15%) compared to women (12%).
In addition, men are prepared to spend more trying to find their pet than women, with almost 20% prepared to spend between £100 and £1000 for the safe return of an animal, compared to 14% of women.
Chartered psychologist, Beverly Stone said: "These findings highlight the inherent differences between men and women. Whereas women tend to fear for the potential loss of their pet when it goes missing and mourns the loss if their pet dies, a man not only experiences a similar fear and mourning but may also feel a strong sense of responsibility."As a consequence, they are likely to feel that they have failed to protect their pet. Men need more time to get over the guilt, and they would not want to be exposed to people asking what happened in social events, if they feel responsible''.
The research, conducted amongst 3000 British pet owners in March 2011, also revealed that a third of pet owners do not invest in pet insurance.
The session will be conducted in the style of the BBC Radio 4 Moral Maze discussion programme, with panelists and witnesses arguing for and against the viewpoint corporatisation is inevitable and will benefit vets and their clients.
Moderated by Madeleine Campbell, Keith Chandler and Karl Holliman will argue for corporatisation and Andrew Harrison and Tim Greet will be against. They will call upon a series of 'witnesses' for detailed questioning before the topic is more broadly debated.
CVS, the UK’s biggest veterinary group now owns more than 410 veterinary practices, of which over 30 are specifically equine or mixed practices.
The latest equine acquisitions include Bell Equine, a one-site Equine Referral Hospital in Kent, in January 2017 and Severn Edge Veterinary Group, a mixed practice with 12 sites in Shropshire, including a six-vet dedicated equine practice, in April 2017.
One line of argument says that the commercial and business advantages of a corporate, together with their scale and diversity, can give veterinary surgeons greater potential for a more flexible career path and advancement within the industry, and a more sustainable working career in equine practice.
On the flip side, there's the removal of any opportunity to buy into ownership, reduced decision-making ability because of adherence to corporate procedures, extra paperwork, longer approval processes and an increased emphasis on the bottom line.
David Mountford, Chief Executive of BEVA said: "The auditorium is usually full to bursting for our Moral Maze sessions because they bring a broader and more engaging dimension to important topics. The statement Corporatisation of equine practices is inevitable and will benefit vets and their clients is bound to generate some stimulating and possibly heated debate."
This year's BEVA Congress will be held at Liverpool Arena Convention Centre, and anyone who registers before 3rd August will receive significantly reduced booking fees.
For more information, visit: www.beva.org.uk.
The ESVE has become aware through its Endocrine Quality Assurance (EQA) Scheme that there will be a permanent change in the antibody used for the cortisol test for the Siemens Immulite 2000.
The change affects the antibody pool from kit Lot 550 onwards, meaning that it has already affected some laboratories and others will be affected in the next few weeks to months. At present, the new antibody lots are not being released to the USA market. Other analysers are unaffected.
The ESVE has been working with the laboratories in its EQA scheme to quantify the impact on results and reference limits. The Society says an initial review by the ESVE-EQA based on >400 canine serum and >40 urine results suggests that canine serum cortisol results are lower (average bias -23% in canine serum) than diagnostic laboratories and clinicians have been used to in the past. The effect is more marked in canine urine cortisol (average bias -70%).
Since being alerted by the ESVE-EQA, the manufacturer has derived mathematical adjustment factors that laboratories can incorporate into their systems to mitigate the impact on results. If the manufacturer adjustment is used, then the results will be around 8% lower on average in serum and around 60% lower in urine. Cut-offs to diagnose hyperadrenocorticism and rule out hypoadrenocorticism may need to be validated again with the new assay. There is not yet sufficient data in the ESVE-EQA collaboration to assess the impact on feline and equine samples.
Professor Ian Ramsey, President of the BSAVA and one of the founders of ESVE, said: “Individual laboratories may have different ways of dealing with this change and therefore it is important to keep in touch with your laboratory provider concerning their approach. Some may choose to make the mathematical adjustments to results so that common and historic cut-off values can continue to be used. Others may report their results directly but change their guidance on interpretative cut-off values."
Dr Peter Graham, ESVE-EQA Co-ordinator, concluded: “ESVE advises that all cortisol results from Siemens Immulite 2000 assays that are close to a threshold are interpreted cautiously. ESVE also advises that all endocrine results should be interpreted in the light of clinical findings and would like to remind clinicians that spurious results may occur in any assay, though this is rare.”
The BSAVA and ESVE encourage laboratories to tell clinicians which analyser they are using. Suitable wording regarding the interpretation of any values of cortisol based on Siemens Immulite 2000 results should be provided by laboratories for the foreseeable future.
Photo: A dog with hyperadrenocortism, courtesy Professor Ian Ramsey
They say that they've been aware of minor interruptions to the supply of such vaccines throughout 2022.
However, a significant, pan-European logistical problem being experienced by Boehringer Ingelheim has raised the prospect of a further reduction in supplies in the coming months.
BEVA is liaising with the three vaccine manufacturers to quantify the impact of the shortage and to consider solutions, both to minimise the threat to equine health and to prevent disruption to equestrian competition.
Marc Laemmer, equine business head at Boehringer Ingelheim Animal Health, said: “We are currently experiencing a European-wide supply issue relating to our equine influenza and influenza-tetanus vaccines.
"This has been caused by unexpected issues following the implementation of a technology upgrade and is not a product or quality issue.
"This means that some vet practices will have difficulty obtaining sufficient influenza vaccines and there may be a shortage in the UK market.
"We understand the importance of these vaccines to equine welfare, and we are continuing to work tirelessly to find a solution so that we can return to normal supply as soon as possible.”
Amanda Melvin, equine business manager at MSD Animal Health, said: “Based on prior demand, MSD’s equine vaccines Equilis Prequenza and Equilis Prequenza Te are in full supply.
"MSD have taken steps to protect as many horses as possible at this time.
"We will continue to supply existing customers with the available MSD stock on ‘allocation’ and, where possible, to allocate stock to additional customers. Allocations are being made to our veterinary customers based on their historical demand which we believe is the most efficient way to manage the available supplies.”
Rebecca Cabrejas, equine business unit manager at Zoetis, said: “Demand for our vaccines currently exceeds what we can supply.
"Whilst we have adequate stocks to fulfil current customers’ orders unfortunately, we are not in a position to be able to supply new customers at this time.
"We will continue to work with BEVA to limit the impact of the current shortages.”
For the randomised controlled trial, 528 dairy heifers were monitored for 34 months to investigate the effects of routine treatment with a NSAID at calving and during treatment for lameness, on the future probability of lameness and culling.
The cows were exposed to normal farm conditions and were split into four groups:
During the study, the probability of lameness was assessed by a lameness outcome score collected every 14 days.
Data on culling was also extracted from farm records.
438 animals were included in the final analysis which revealed that treating a cohort of cows following the group three protocol led to an absolute reduction in lameness of approximately 10% and severe lameness of 3%, compared with animals treated in accordance with conventional best practice (group one).
James Wilson BSc(Hons) PhD, foot health consultant and lead researcher on the trial, said: “It appears that through giving heifers a NSAID at critical time points, we have imparted a substantial, long-lasting benefit to them.
"When freshly calved heifers enter the herd for the first time, we understand that they are (typically) naïve to lameness and have good hoof health.
"By utilising NSAIDs strategically, we believe that we have preserved the functionality of the foot, thereby reducing the risk of lameness.
"This is a highly efficacious, cost-effective means of managing lameness on farm.”
Herd Health Consultancy says that in dairy cows, it is advisable to consider using a zero milk-withhold NSAID which is fully licensed to treat lameness in cattle to avoid any need to discard milk, however no NSAID is currently licensed in the UK to treat the pain associated with calving, so careful advice should be given to farmers based on the farm type and production methods.
https://doi.org/10.3168/jds.2021-21329
Reference
Horiba Medical - UK has launched MLT-Diode Laser Systems, specifically designed for veterinary use, as part of its portfolio of animal healthcare products.
According to the company, the MLT-Diode Lasers are highly versatile and can be used in a variety of veterinary applications including surgery, endoscopy, dentistry and irradiation.
The two models, the MLT-Diode Laser Classic and Premium, both feature touch screen controls and are adaptable to each users individual preferences. Designed with small animal practices in mind, the Classic has a performance out-put of 8 watts whilst the more powerful Premium model is for equine medicine with an output of 15 watts. The system is mounted on a mobile cart with a protection case, allowing the whole system to be moved between treatment rooms and enabling near patient application.
Horiba Medical will be exhibiting the MLT-Diode Laser Systems at the London Vet Show at Olympia, 22nd to 23rd October 2010, on Stand M4.
BSAVA Congress, which is open to the whole practice, from reception to the clinical team, will offer free practical drop-in sessions, day-in-the-life dramas, and a bigger wellbeing zone.
There'll be over 120 hours of CPD covering a range of topics such as oncology, veterinary leadership, the RVN’s role, and charity veterinary care.
Paul Higgs, Chair of the Congress Committee, said: “I cannot wait for BSAVA 2023!
"After the successful transformation of BSAVA in our move to Manchester we have been working our socks off to go one better!
"Filled with brilliant speakers, our now trade-mark combination of short, paired lectures with stimulating and inspiring panel discussions, is back in strength.”
Early-bird tickets for BSAVA Congress 2023 are on sale now and BSAVA has brought back one-day only tickets, so if you can’t attend all three days, you have the option to visit on a day that suits you.
https://www.bsavaevents.com/bsavacongress2023/en/page/home
The book highlights some of the ways that action is being taken in the profession to retain and develop female talent, build women’s economic empowerment, support women into leadership, decision-making and business, and create infrastructure that meets the needs of women.
Profiles include Dr Katrin Jahn, who is paving the way for female veterinary professionals in the Middle East and Dr Jyotika Sangle, who works in regulatory affairs in India, where the veterinary profession is not considered to be a career choice for women, and its importance is not well understood.
Also profiled is Perdi Welsh, who is working to enhance career progression options for veterinary nurses, and Samantha Lympany-Tier, who is advocating for the role of veterinary care assistants and patient emotional welfare in clinical practice.
Veterinary Woman editor, Jenny Langridge, said: “When we’re feeling worn down by work pressures it can be difficult to envisage change for the better, but the veterinary professions are bursting with people driving innovation and development in many different ways.
"I hope that our ‘Champions for Change’ eBook will help vet professionals of all types to find inspiration from the stories of the amazing efforts taking place within the sector to drive new thinking and improvements to wellbeing, career prospects, equality and inclusivity.”
https://www.veterinarywoman.co.uk/2024/03/champions-for-change-e-book
Petplan has announced the finalists for the 2009 Veterinary Awards.
The company says it was inundated with more than 2300 nominations this year and that the public response was 'astonishing', with tales ranging from midnight rescues to simple acts of kindness and this year was no exception.
The finalists for each of the categories are as follows:
Vet of the YearJamie Rushton, Village Vet Hampstead, LondonBen Jones, Ben Jones Veterinary Surgery, Chester, FlintshireMatthew Fry, Quarrington Veterinary Surgery, Sleaford, Lincolnshire
Vet Nurse of the YearCharlotte Maude, Companion Care Veterinary Surgery Chesterfield, Markham, ChesterfieldKaren McQuaid, The Old Golfhouse Veterinary Group, Watton, NorfolkRachel Smith, 608 Veterinary Group, Solihull, West Midlands
Vet Receptionist of the YearYasmin Morowa, Melton Veterinary Surgery, Woodbridge, SuffolkJackie Crampton, Companion Care Veterinary Surgery Chesterfield, Markham, ChesterfieldSara Abbott, Pet Doctors, East Horsley, Surrey
Vet Practice of the YearAshfield House Veterinary Hospital Limited, Long Eaton, NottinghamshireCarrick Veterinary Group CVS (UK) Ltd, Newbold, ChesterfieldSt Clair Veterinary Group, Kirkcaldy, Fife
Simon Wheeler, Petplan's Head of Marketing said he was thrilled by the record number of nominations received:
"This year we are celebrating the tenth anniversary of the Veterinary Awards which were launched so pet owners could thank their practice for the tireless and wonderful work they carry out. We are delighted that the awards, which we often hear referred to as the 'Vet Oscars', are still going strong. This year we have received over 2300 nominations and the quality and standard really challenged the skills of our esteemed judging panel. We would like to wish those short listed every success on the night."
All finalists will be invited to a 'glittering' awards ceremony that will take place on 2nd April at the Burlington Hotel in Birmingham where the winners will be announced.
Ronnie (pictured right) will look at quality control and artefacts of sample quality and review the effects of different pathologies. By examining analyser output, he'll demonstrate how abnormalities of cells and plasma may affect measured parameters and their indices.
Using images, photomicrographs and video links, he'll move onto explain the techniques and equipment needed to complement analytical automation in order to confirm results quality.
Ronnie said: "“We now have more near patient testing in veterinary haematology than ever before. Quality is key to best practice and ultimately superior patient care. Sod’s Law states that ‘if something can go wrong, it will!’, so along the way to your generating a Complete Blood Count, it pays to be aware of some of the pitfalls that you may encounter.
“One should never underestimate the value of gross exam and simple methods that can be used to ensure sample quality and results accuracy. Seeing is believing after all!”
There will also be an open Q&A session with Ronnie after the presentation, so attendees are invited to bring any questions on all things haematology.
To register for the webinar, visit: https://register.gotowebinar.com/register/2458623866746094093
Animalcare has announced that a new indication for chronic renal insufficiency in cats has been approved in the licence for Benazecare 5mg.
Benazecare is a POM-V ACE (angiotensin converting enzyme) inhibitor containing benazepril hydrochloride, which was originally launched in the UK in 2007 for the treatment of congestive heart failure in dogs.
For more information, contact Animalcare at www.animalcare.co.uk
BSAVA has launched its Postgraduate Certificate website.
The site contains all of the online materials and activities which support the BSAVA postgraduate certificates. The BSAVA says students enrolled on the programmes will find it invaluable.
There are also sections of the site for those who have agreed to act as mentors for students enrolled on the programme, and exclusive material for BSAVA members who missed out on enrolment in 2012, but have pre-enrolled for 2013.
The BSAVA Postgraduate Certificate website may be found via the CPD section at http://www.bsava.com/ (direct link http://www.bsavaeducation.co.uk/). If you would like to know more about the BSAVA Postgraduate Certificate programmes, please email certificate@bsava.com.
Mary (or, to give her her full title, Dr Mary Fraser BVMS PhD CertVD PGCHE FHEA MAcadMEd CBiol FRSB FRSPH FRCVS) focussed on decision-making in practice while studying for her MRes in Clinical Veterinary Research, looking at how vets and owners influence the decision making process. This led her to consider how decision making is taught to students.
As part of the initiative, Mary has launched a new website: www.clinicaldecisions.org, which, together with a supporting blog, is designed to help students and recent graduates examine their decision making in practice, consider how owners influence it, and take forward shared decision making for the benefit of all.
Mary said: "As a student decision making can seem difficult. Working with owners, all of whom have different expectations, can add to those challenges.
"I hope that by bringing that discussion to the fore we can support each other and allow future vets and veterinary nurses to identify their own strengths in supporting owners to make the best decisions for their animals."
Find out more and contribute to the discussion at www.clinicaldecisions.org
Pedigree® today launched its 2009 Pedigree Adoption DriveTM to highlight the issue of dog abandonment in the UK.
It's estimated that there are 100,000 abandoned or stray dogs in the UK every year. Pedigree surveyed animal rescue homes across the UK and in just 33 centres, found that over the course of just eight days between Christmas and New Year, an average of 12 dogs were abandoned per centre, equalling more than one every day.
Clarissa Baldwin, Chair of the Association of Dogs and Cats Homes (ADCH) comments: ‘These statistics illustrate the severity of the situation. As a nation of so-called dog lovers, it is unacceptable that pets are being treated as throwaway commodities. Dog ownership is a privilege, not a right.'
Jane Bingham, Pedigree Adoption Drive Manager said ‘We are saddened by the alarming number of dogs being abandoned each year. Our aim is to help raise awareness of the issue of dog abandonment to ensure that re-homing centres are given support to enable them to continue their wonderful work.
‘The rewards pets provide to responsible dog owners are evident yet the figures show there are still thousands of dogs who are in need of loving homes.'
Pedigree's research has found that over seven million dog owners state that their dog makes them happier and over 1 in 4 (nearly three million dog owners) actually admit they love their dog more than some members of their own family!
The Pedigree Adoption Drive aims to not only increase the public's awareness of dog abandonment, but also to raise funds to help rescue centres and charities across the UK re-home these dogs. Now in its second year, The Pedigree Adoption Drive is aiming to increase monies donated from last year's £489,000 to £600,000 by donating 2p for every single Pedigree product sold during January and February 2009.
For more information visit The Pedigree Adoption Drive website - http://www.pedigreeadoptiondrive.com./
Intervet/Schering-Plough Animal Health has announced that it has received approval for the intramuscular (IM) route of administration of Nuflor Minidose 450 mg/ml, a florfenicol-containing broad-spectrum antibiotic for the management of bovine respiratory disease (BRD).
Nuflor Minidose was approved initially in 2008 for subcutaneous (SC) use only and the now approved IM administration route is a line extension. According to Intervet/Schering Plough, IM administration (20 mg/kg administered twice, 48h apart) offers additional flexibility for the veterinary surgeon when treating cattle for BRD.
The company adds that Nuflor Minidose is the florfenicol injectable formulation which offers the lowest injection volume, which in particular is practical when treating heavier animals (thereby avoiding large injection volumes). The withdrawal period after IM administration of NUFLOR Minidose is only 37 days and is considerably shorter as compared to 64 days after SC use (40 mg/kg body weight injected once).
Francis Adriaens, Global Marketing Director, Global Ruminants Business Unit at Intervet/Schering-Plough Animal Health said: "Our customers requested the IM claim when Nuflor Minidose was first introduced and we are delighted to be able to recommend this route of administration hence forth."
Nuflor Minidose is indicated for preventive and therapeutic treatment of BRD in cattle caused by Mannheimia haemolytica, Pasteurella multicoda and Histophilus somni susceptible to florfenicol. The presence of the disease in the herd should be confirmed before administering preventive treatment.
The Heart Health Panel - a group of expert veterinary surgeons, cardiologists and nutritionists set up by Boehringher Ingelheim Vetmedica - has launched a set of guidelines on the management of canine cardiac health through nutrition and lifestyle changes.
Entitled Supporting canine heart health through nutrition and lifestyle, Boehringher says the guidelines provide veterinary professionals with information on canine heart health, including the progression of heart disease through four main stages. These are: the green phase - no clinical signs and no pathology; the yellow phase - no clinical signs of heart failure but evidence of disease at clinical exam; the orange phase - occasional clinical signs when exercising and the red phase - clinical signs at rest.
The panel has developed a diagnostic checklist to determine whether a patient has heart disease and which phase they are in to help initiate a good diet and healthy lifestyle early enough to support heart health. While a dog's individual needs should be taken into account when advising on dietary management and lifestyle, the panel's recommendations include a balanced, complete diet, dietary supplements, such as omega-3, and an appropriate exercise regime.
The Heart Health Panel's guidelines are now available as a booklet and are supported with a leaflet for dog owners entitled Support your dog's heart. The leaflet features information on canine heart health including risk factors, dietary advice, clinical signs of disease, diagnosis and the creation of a heart health management plan. Both the owner leaflet and the panel guidelines are available from Boehringer Ingelheim Vetmedica, and copies can be ordered from your local territory manager or by emailing vetmedica.uk@boehringer-ingelheim.com.
The RVC says that until now, there has been little reliable evidence on the frequency and severity of syringomyelia in the overall dog population, which has limited veterinary surgeons’ ability to diagnose and manage the condition.
It's not just syringomyelia for which there is a lack of data. Scientists have for years struggled to identify the true extent and severity of diseases seen in the wider general dog population because the main source of veterinary health data on dogs has come from universities and referral hospitals.
While this referral data is useful, the types of animals and conditions that are referred to these referral centres is unrepresentative of the wider dog population, making it very difficult to extrapolate any findings to the general population. The vast majority of animals are managed perfectly well by the primary vet practitioners without ever being referred or even being ill at any one time.
However, through VetCompass, the RVC is now collecting anonymised clinical data from first opinion veterinary clinics across the UK; data which is being analysed to answer a wide variety of previously unanswerable health questions.
The VetCompass syringomyelia study published in the Veterinary Record is a case in point. It highlights for the first time the frequency and severity of syringomyelia seen in general practice in the UK.
At an overall dog population level, syringomyelia is not that common, affecting just one in 2,000 dogs. But among Cavaliers, the frequency of syringomyelia is much higher, affecting one in every 60 of the breed. VetCompass data reveals that almost 2,000 Cavaliers suffer from clinical syringomyelia in the UK at any one time.
Syringomyelia is a severe condition for affected dogs, with the VetCompass study showing that 72% of affected dogs were recorded as showing pain. The study showed that these dogs would often yelp or scream when they were picked up or when their necks were touched. Many of them also showed ‘phantom scratching’ where they would try to scratch at their necks with their hindlegs but without ever even making contact with the skin. Some people refer to this action as ‘playing an air guitar’.
The RVC is urging veterinary surgeons and owners alike to be aware of the symptoms of syringomyelia, so that clinically affected dogs can be recognised and treated earlier and better. Symptoms include:
Dr Dan O’Neill, Companion Animal Epidemiologist at the RVC, said: "I loved being a first opinion practice vet for over 20 years where I could help animals on a one-by-one basis. But now, with VetCompass, we can help animals by their thousands. An example is this syringomyelia study which may lead to many affected dogs getting treatment much earlier and therefore making their lives so much better."
Professor Holger Volk, Professor of Veterinary Neurology and Neurosurgery, said: “These VetCompass data are an eye-opener; we very frequently see Cavaliers with clinical signs of syringomyelia at RVC’s referral hospital but now we know how common it is in the real world, outside of the referral world."
Dr Ludovic Pelligand, Senior Lecturer in Clinical Pharmacology and Anaesthesia, said: “VetCompass allows us to identify how Cavalier King Charles affected by syringomyelia are treated for pain every day, nationwide. This will help us to understand optimal management and we are currently working on new ways to monitor pain and working towards developing new treatment options to further improve their pain relief and quality of life in the future".
The awards, which were first launched last year, are open to UK practices, branch surgeries or other organisations who employ veterinary surgeons or nurses. They were created to highlight wellbeing in the veterinary profession and celebrate workplaces where:
• health and happiness are valued;• there are systems and initiatives that motivate;• staff are engaged;• communication is positive;• there is commitment to being a better place to work.
The prize for each category includes two registrations and banquet tickets for SPVS/VPMA Congress 2018 where the winners will be announced to the media and will be available for interview.
Practices that are thinking about applying can now access a free five-minute Wellbeing Checklist that can help provide examples of some simple activities that can improve the health and wellbeing of the veterinary team.
Nick Stuart from SPVS said: "Taking five minutes to fill out the Wellbeing Checklist is a great way to get a sense of how your practice is doing, and to identify ways in which you could improve. Practices are often doing a lot more than they realise and the Checklist shows how even such small steps as a having a fruit bowl in the staff room, or having a five-minute huddle at the start of the day, can make a huge difference."
Lizzie Lockett, MMI Director, said: "Having a supportive and constructive culture is key not just for the welfare of the staff, but for the animals they take care of. It allows all members of the team to feel comfortable coming forward with questions, clarifications, or even mistakes, and can ultimately lead to safer and more consistent care for patients."
Entries can be made now via the website www.vetwellbeingawards.org.uk, where the Wellbeing Checklist is also available.
The closing date for entries is Friday 15 December 2017. You can follow the awards on twitter @vetwellbeing and Facebook /vetwellbeingawards/.